Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah B Goldberg

Showing results (41-50 of 105) with videos related to

Pageof 11
Sort By:
JAMA Oncology|September 17, 2020
Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic FeaturesRanjan Pathak, Sarah B Goldberg, Maureen Canavan, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|March 2, 2024
Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and RecruitmentAyesha Butt, Jana Christian, Anna Kress, et al.
Cancer Immunology Research|December 25, 2015
Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab TreatmentJustine V Cohen, Ahmed K Alomari, Alexander O Vortmeyer, et al.
The Lancet. Oncology|March 4, 2021
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment planJoanna A Gibson, Karin E Finberg, ILKe Nalbantoglu, et al.
Trends in Cancer|March 7, 2018
The Evolving Landscape of Brain MetastasisManuel Valiente, Manmeet S Ahluwalia, Adrienne Boire, et al.
Future Oncology (London, England)|July 18, 2024
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancerFabrice Barlesi, Byoung Chul Cho, Sarah B Goldberg, et al.
Journal of Neuro-Oncology|May 15, 2026
Disparities in stereotactic radiosurgery receipt in patients with brain metastases from non-small cell lung cancerKelly Becht, Meghan E Lindsay, Pamela R Soulos, et al.
Journal of Neuro-Oncology|August 5, 2021
Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysisMani Ratnesh S Sandhu, Veronica L Chiang, Thuy Tran, et al.
Journal of Neuro-Oncology|August 17, 2021
Correction to: Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysisMani Ratnesh S Sandhu, Veronica L Chiang, Thuy Tran, et al.
Therapeutic Advances in Medical Oncology|May 25, 2026
TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with <i>EGFR</i>-mutated locally advanced or metastatic non-small cell lung cancerShun Lu, Mariano Provencio Pulla, Eldsamira Mascarenhas, et al.
Pageof 11

Showing results (41-50 of 105) with videos related to

Sort By:
Pageof 11
JAMA Oncology|September 17, 2020
Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic FeaturesRanjan Pathak, Sarah B Goldberg, Maureen Canavan, et al.
Journal of Cancer Education : the Official Journal of the American Association for Cancer Education|March 2, 2024
Providing 0.1 Full-Time Equivalent (FTE) Support to Fellowship Core Faculty Improves Faculty Involvement in Fellowship Education and RecruitmentAyesha Butt, Jana Christian, Anna Kress, et al.
Cancer Immunology Research|December 25, 2015
Melanoma Brain Metastasis Pseudoprogression after Pembrolizumab TreatmentJustine V Cohen, Ahmed K Alomari, Alexander O Vortmeyer, et al.
The Lancet. Oncology|March 4, 2021
Yale Cancer Center Precision Medicine Tumor Board: molecular findings alter a diagnosis and treatment planJoanna A Gibson, Karin E Finberg, ILKe Nalbantoglu, et al.
Trends in Cancer|March 7, 2018
The Evolving Landscape of Brain MetastasisManuel Valiente, Manmeet S Ahluwalia, Adrienne Boire, et al.
Future Oncology (London, England)|July 18, 2024
PACIFIC-9: Phase III trial of durvalumab + oleclumab or monalizumab in unresectable stage III non-small-cell lung cancerFabrice Barlesi, Byoung Chul Cho, Sarah B Goldberg, et al.
Journal of Neuro-Oncology|May 15, 2026
Disparities in stereotactic radiosurgery receipt in patients with brain metastases from non-small cell lung cancerKelly Becht, Meghan E Lindsay, Pamela R Soulos, et al.
Journal of Neuro-Oncology|August 5, 2021
Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysisMani Ratnesh S Sandhu, Veronica L Chiang, Thuy Tran, et al.
Journal of Neuro-Oncology|August 17, 2021
Correction to: Incidence and characteristics of metastatic intracranial lesions in stage III and IV melanoma: a single institute retrospective analysisMani Ratnesh S Sandhu, Veronica L Chiang, Thuy Tran, et al.
Therapeutic Advances in Medical Oncology|May 25, 2026
TROPION-Lung14 study protocol: a phase III study of osimertinib in combination with datopotamab deruxtecan versus osimertinib alone as first-line treatment for patients with <i>EGFR</i>-mutated locally advanced or metastatic non-small cell lung cancerShun Lu, Mariano Provencio Pulla, Eldsamira Mascarenhas, et al.
Pageof 11